Sidiqi, M. Hasib
Al Saleh, Abdullah S.
Leung, Nelson http://orcid.org/0000-0002-5651-1411
Jevremovic, Dragan
Aljama, Mohammed A.
Gonsalves, Wilson I.
Buadi, Francis K.
Kourelis, Taxiarchis V.
Warsame, Rahma
Muchtar, Eli http://orcid.org/0000-0003-2210-2174
Hobbs, Miriam A.
Lacy, Martha Q.
Dingli, David
Go, Ronald S. http://orcid.org/0000-0002-8284-3495
Hayman, Suzanne R.
Rajkumar, S. Vincent http://orcid.org/0000-0002-5862-1833
Dispenzieri, Angela
Gertz, Morie A.
Kumar, Shaji K. http://orcid.org/0000-0001-5392-9284
Fonseca, Rafael
Kapoor, Prashant
Article History
Received: 18 December 2019
Revised: 3 March 2020
Accepted: 3 April 2020
First Online: 11 May 2020
Conflict of interest
: M.H.S., A.S.A., D.J., M.A.A., T.V.K., R.W., E.M., M.A.H., R.S.G., S.R.H., S.V.R., N.L., W.I.G., F.K.B.: none. M.A.G.: consultancy (Milleniu) and honoraria (Celgene, Millenium, Onyx, Novartis, Smith Kline, Prothena, Ionis); M.Q.L.: research funding (Celgene); D.D.: research funding (Karyopharm Therapeutics, Amgen, and Millenium Pharmaceuticals); S.K.K.: consultancy (Celgene, Millennium, Onyx, Janssen, and BMS), and research funding (Celgene, Millennium, Novartis, Onyx AbbVie, Janssen, and BMS). A.D.: research funding (Celgene, Millennium, Pfizer, and Janssen), Travel grant (Pfizer). R.F.: stock and other ownership interests: Adaptive Biotechnologies; Honoraria: Celgene, Bristol-Myers Squibb, Bayer, Amgen, Janssen, Kite Pharma, Merck Sharp & Dohme, Juno Therapeutics, Takeda, AbbVie, Aduro Biotech, Sanofi; consulting or advisory role: Celgene, Bristol-Myers Squibb, Bayer, Amgen, Janssen, AbbVie, Kite Pharma, Merck Sharp & Dohme, Juno Therapeutics, Takeda, Aduro Biotech, Sanofi; patents, royalties, other intellectual property: patent for the prognostication of multiple myeloma based on genetic categorization of the disease. Travel, accommodations, expenses: multiple. P.K.: research funding (Takeda, Sanofi, AbbVie and Amgen).